Douglas MacDonald

6PUBLICATIONS
79CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 26, 2025
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo.

Robert Salzler, David J DiLillo, Kei Saotome

|Nov 09, 2022
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.

Joyce Wei, Welby Montalvo-Ortiz, Lola Yu

|Jun 26, 2020
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.

Janelle C Waite, Bei Wang, Lauric Haber

|Jan 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.

Dimitris Skokos, Janelle C Waite, Lauric Haber

|Jun 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

Alison Crawford, Lauric Haber, Marcus P Kelly

|Nov 04, 2018
<b>Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8</b>.

Bei Wang, Wen Zhang, Vladimir Jankovic

Pageof 1

Frequent Collaborators

5 joint publications

Andrew J Murphy

4 joint publications

William Olson

3 joint publications

Jacquelynn Golubov

3 joint publications

Matthew A Sleeman